AR028817A1 - Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen - Google Patents

Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen

Info

Publication number
AR028817A1
AR028817A1 ARP000101297A ARP000101297A AR028817A1 AR 028817 A1 AR028817 A1 AR 028817A1 AR P000101297 A ARP000101297 A AR P000101297A AR P000101297 A ARP000101297 A AR P000101297A AR 028817 A1 AR028817 A1 AR 028817A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
pyrrolidine
phenyl
compounds derived
arenosulfonil
Prior art date
Application number
ARP000101297A
Other languages
English (en)
Inventor
Vincent Mutel
Eric Vieira
Jurgen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR028817A1 publication Critical patent/AR028817A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos derivados de la 1 -arenosulfonil- 2 - arilo- pirrolidina de formula general 1 en donde R1 significa, hidrogeno, alquilo inferior o hidroxilo --alquilo inferior; R2 significa furilo, tienilo, piridilo o fenilo, el cual está opcionalmente sustituido por 1 a 3 sustituyentes seleccionado de alquilo inferior, alcoxilo inferior, halogeno, ciano, CF3 o -N (R4)2; R3 significa naftilo o fenilo, el cual está opcionalmente sustituido con 1 a 3 sustituyentes de alquilo inferior, alcoxilo inferior, halogeno, acetilo, ciano, hidroxilo - -alquilo inferior, -CH2 - morfolin- 4- ilo, alquilo inferior- oxi- alquilo inferior, alquilo inferior - N(R4)2 o CF3; R4 significa, independientemente entre sí, hidrogeno o alquilo inferior, con la excepcion de la (RS) - 2 - fenil - 1 - (toluen - 4 -sulfonil)- pirrolidina y (RS) - 1- (toluen- 4 - sulfonil)- 2 - ptolil- pirrolidina así como sus sales farmacéuticamente aceptables. Los compuestos descritos más arriba son antagonistas o agonistas del receptor metabotropico de glutamato, y por lo tanto son de utilidad en el tratamiento de los correspondientes trastornos del SNC.
ARP000101297A 1999-03-25 2000-03-23 Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen AR028817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99106004 1999-03-25

Publications (1)

Publication Number Publication Date
AR028817A1 true AR028817A1 (es) 2003-05-28

Family

ID=8237852

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101297A AR028817A1 (es) 1999-03-25 2000-03-23 Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen

Country Status (34)

Country Link
US (1) US6284785B1 (es)
EP (1) EP1165510B1 (es)
JP (1) JP3590589B2 (es)
KR (1) KR100452648B1 (es)
CN (1) CN1150165C (es)
AR (1) AR028817A1 (es)
AT (1) ATE305451T1 (es)
AU (1) AU765212B2 (es)
BR (1) BR0009278A (es)
CA (1) CA2368418C (es)
CO (1) CO5050296A1 (es)
CZ (1) CZ20013402A3 (es)
DE (1) DE60022867T2 (es)
DK (1) DK1165510T3 (es)
ES (1) ES2249249T3 (es)
HK (1) HK1044944B (es)
HR (1) HRP20010682A2 (es)
HU (1) HUP0200284A3 (es)
IL (1) IL145301A0 (es)
JO (1) JO2274B1 (es)
MA (1) MA26779A1 (es)
MX (1) MXPA01009623A (es)
MY (1) MY125295A (es)
NO (1) NO319948B1 (es)
NZ (1) NZ514037A (es)
PE (1) PE20001583A1 (es)
PL (1) PL204436B1 (es)
RU (1) RU2248350C2 (es)
SI (1) SI1165510T1 (es)
TR (1) TR200102789T2 (es)
TW (1) TW575561B (es)
WO (1) WO2000058285A1 (es)
YU (1) YU67601A (es)
ZA (1) ZA200107689B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
CA2567343A1 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP2336107B1 (en) 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Proton pump inhibitors
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AR055144A1 (es) 2005-08-30 2007-08-08 Takeda Pharmaceutical Inhibidor de secrecion acida
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
KR101629181B1 (ko) 2008-08-27 2016-06-13 다케다 야쿠힌 고교 가부시키가이샤 피롤 화합물
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
US10603313B2 (en) * 2017-07-31 2020-03-31 Chiromics, LLC Allosteric modulators of the mu opioid receptor
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
PL350679A1 (en) 2003-01-27
TW575561B (en) 2004-02-11
MY125295A (en) 2006-07-31
HRP20010682A2 (en) 2002-10-31
JO2274B1 (en) 2005-04-07
HUP0200284A3 (en) 2003-04-28
PL204436B1 (pl) 2010-01-29
DK1165510T3 (da) 2006-02-06
WO2000058285A1 (en) 2000-10-05
MXPA01009623A (es) 2002-05-06
CZ20013402A3 (cs) 2002-03-13
MA26779A1 (fr) 2004-12-20
HUP0200284A2 (en) 2002-06-29
NO20014617D0 (no) 2001-09-24
CN1150165C (zh) 2004-05-19
JP2002540191A (ja) 2002-11-26
RU2248350C2 (ru) 2005-03-20
JP3590589B2 (ja) 2004-11-17
CN1345311A (zh) 2002-04-17
PE20001583A1 (es) 2001-01-15
KR100452648B1 (ko) 2004-10-12
AU765212B2 (en) 2003-09-11
DE60022867D1 (de) 2006-02-09
DE60022867T2 (de) 2006-06-22
CA2368418A1 (en) 2000-10-05
TR200102789T2 (tr) 2002-04-22
IL145301A0 (en) 2002-06-30
HK1044944A1 (en) 2002-11-08
ES2249249T3 (es) 2006-04-01
CO5050296A1 (es) 2001-06-27
AU3291500A (en) 2000-10-16
US6284785B1 (en) 2001-09-04
ZA200107689B (en) 2002-12-18
YU67601A (sh) 2004-09-03
BR0009278A (pt) 2001-12-26
KR20010108403A (ko) 2001-12-07
SI1165510T1 (sl) 2005-12-31
NO20014617L (no) 2001-09-24
EP1165510A1 (en) 2002-01-02
HK1044944B (zh) 2004-10-21
NO319948B1 (no) 2005-10-03
EP1165510B1 (en) 2005-09-28
ATE305451T1 (de) 2005-10-15
CA2368418C (en) 2009-03-10
NZ514037A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
AR028817A1 (es) Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
NO20052737L (no) N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them.
NO20032253L (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
IS6481A (is) 2-oxó-1-pýrrólidín afleiður, aðferðir til framleiðslu á þeim og notkun þeirra
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
ATE203990T1 (de) Indolderivat als 5-ht1a antagonist und als inhibitor der serotonin-wiederaufnahme
AR008829A1 (es) Derivados 6,6- o 6,7 biciclicos sustituidos que contienen pirido o pirimido como agentes antagonistas para el tratamiento de enfermedades gastrointestinales, inflamatorias y del snc, y composicion farmaceutica
ATE252575T1 (de) Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung
RS51013B (sr) Indolinon supstituisan na poziciji 6, njegovo dobijanje i njegova upotreba kao leka
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
ATE399770T1 (de) Tachykininrezeptorantagonisten
PE20040698A1 (es) Derivados de isoindolina
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc
AR026209A1 (es) Compuestos monociclicos basicos con accion nk-2 antagonista, procesos de fabricacion y formulas que los contienen
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
ATE406363T1 (de) Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
ECSP045292A (es) Proceso para la preparación de piperazines quirales 1,4-disustituidas
CO4980896A1 (es) Nuevos derivados de piperidina un procedimiento para su preparacion y las composicones farmaceuticas que los contienen
ECSP003399A (es) Derivados de la 1- arenosulfonil - 2- arilo - pirrolidina y de la piperidina
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora

Legal Events

Date Code Title Description
FB Suspension of granting procedure